Home Featured Page 170

Featured

Latest

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 1

PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials...

Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin...

Kambô: Another Psychedelic Amphibian?

PT326 – Dr. Rick Barnett, Psy.D – Addiction, Recovery, and Competency...

PT325 – Philip Wolf – Cannabis: The Early Days of Legality,...

The Intertwined Prohibitionist Histories of Psychedelics and Kratom

Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato;...

PT324 – Amanda Reiman, Ph.D., MSW – Web3, NFTs, Cryptocurrencies, and...

Psychedelic Research Bulletin: May 2022

1...169170171...305 Page 170 of 305

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 1

PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials...

Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin...

Kambô: Another Psychedelic Amphibian?

PT326 – Dr. Rick Barnett, Psy.D – Addiction, Recovery, and Competency...

PT325 – Philip Wolf – Cannabis: The Early Days of Legality,...

The Intertwined Prohibitionist Histories of Psychedelics and Kratom

Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato;...

PT324 – Amanda Reiman, Ph.D., MSW – Web3, NFTs, Cryptocurrencies, and...

Psychedelic Research Bulletin: May 2022

EDITOR PICKS

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY